Nervgen Pharma (NGEN) Intangibles (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Intangibles of $288192.3 for Q1 2026, down 1.78% quarter-over-quarter from $293405.2 in Q4 2025.

Nervgen Pharma (NGEN) Intangibles (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Intangibles for 3 consecutive years, with $288192.3 the latest figure, recorded in Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $288192.3; the TTM figure through Mar 2026 stood at $288192.3 (changed N/A YoY), while the FY2025 annual figure was $293405.2, down 11.85% from the prior year.
Intangibles retreated to $288192.3 in Q1 2026 per NGEN's latest filing, from $293405.2 in the prior quarter.
Across five years, Intangibles topped out at $332839.8 in Q4 2024 and bottomed at $288192.3 in Q1 2026.
Historically, Intangibles has averaged $304812.4 across 3 years, with a median of $293405.2 in 2025.
On a YoY basis, Intangibles climbed as much as 11.85% in 2025 and fell as far as 11.85% in 2025.
Nervgen Pharma's Intangibles stood at $332839.8 in 2024, then fell by 11.85% to $293405.2 in 2025, then fell by 1.78% to $288192.3 in 2026.
Business Quant data shows NGEN's Intangibles at $288192.3 in Q1 2026, $293405.2 in Q4 2025, and $332839.8 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	93.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Nervgen Pharma	168.94 Mn	168.94 Mn	-	-

Download Data